Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ICCM
$0.5811
$
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Next Earnings
2026-02-25
Beta
2.212
Average Volume
Market Cap
Last Dividend
CIK
0001584371
ISIN
IL0011224156
CUSIP
M53071136
CEO
Eyal Shamir
Sector
Healthcare
Industry
Medical - Devices
Full Time Employees
64
IPO Date
2021-08-26
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 | Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate Incidence of kidney cancer is growing worldwide, with an estimated 400,000 new cases globally ; over 80,000 of which are in the U.S. alone hi ghlighting a growing unmet need ProSense® is approved for benign and malignant kidney tumors in the U.S., Europe, and numerous other countries CAESAREA, Israel, Feb. 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the completion of its last patients' five-year follow up evaluation in its ICESECRET clinical trial of ProSense® for the treatment of small renal masses ("SRMs") in kidney cancer patients. | PRNewsWire | 2026-02-23 08:30:00 |
| IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation | First procedures to be performed in the coming weeks at Alabama's largest non-governmental healthcare system Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense® in low-risk breast cancer and inclusion of cryoablation in proposed medical society guidelines CAESAREA, Israel, Feb. 19, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced Thomas Hospital of Fairhope, Alabama, part of the Infirmary Health network of hospitals, purchased and installed the ProSense® system, becoming the first facility in Alabama to offer breast cancer cryoablation. | PRNewsWire | 2026-02-19 08:30:00 |
| IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense® | ProSense® system recently received FDA marketing authorization for the treatment of low-risk breast cancer Cryoablation for breast cancer is now included in proposed medical society guidelines for the approved patient population CAESAREA, Israel, Feb. 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the most recent purchase and installation of the ProSense® system in the U.S. at St. Louis, Missouri based Shero Imaging, the first clinic in the state of Missouri to offer breast cancer cryoablation with ProSense®. | PRNewsWire | 2026-02-11 08:30:00 |
| NYSE Group Consolidated Short Interest Report | NEW YORK--(BUSINESS WIRE)--NYSE today reported short interest as of the close of business on the settlement date of January 30, 2026. SETTLEMENT DATE EXCHANGE TOTAL CURRENT SHORT INTEREST TOTAL PREVIOUS SHORT INTEREST (Revised) NUMBER of SECURITIES with a SHORT POSITION NUMBER of SECURITIES with a POSITION >= 5,000 SHARES 01/30/2026 NYSE 16,361,583,497 16,215,801,695 2,871 2,597 01/30/2026 NYSE ARCA 2,297,133,128 2,305,450,999 2,524 1,768 01/30/2026 NYSE AMERICAN 915,314,421 888,958,930 303. | Business Wire | 2026-02-10 16:00:00 |
| IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved | Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. | PRNewsWire | 2026-02-09 16:30:00 |
| IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer | ASBrS's updated "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" is pending finalization following the end of its open comment period on January 23, 2026 Inclusion of cryoablation in medical society guidelines is expected to result in more breast surgeons recommending cryoablation to appropriate patients Finalized updated guidelines are expected to mark a major step towards widespread adoption of cryoablation in the United States and a new standard of care in breast cancer by offering a minimally invasive procedure that destroys tumors by freezing, without surgery CAESAREA, Israel, Jan. 28, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons (ASBrS) is in the final stage of updating its "Resource Guide on Transcutaneous and Percutaneous Treatment of Benign and Malignant Tumors of the Breast" which should include cryoablation for the local treatment of breast cancer in patients aged ≥70 years, with biologically low-risk tumors measuring ≤1.5 cm, who are treated with adjuvant endocrine therapy, including patients who are not suitable candidates for surgery. | PRNewsWire | 2026-01-28 08:30:00 |
| IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales | Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local treatment of low-risk breast cancer, addressing a market opportunity of approximately 200,000 patients Record European sales, driven by positive effects of U.S. clearance and continued growing adoption of ProSense® cryoablation for breast cancer in key markets Record number of peer-reviewed publications and presentations at global conferences demonstrates growing clinical evidence for cryoablation of breast, musculoskeletal, and kidney cancers with ProSense® CAESAREA, Israel, Jan. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today issued the following letter to shareholders from its Chief Executive Officer, Eyal Shamir. | PRNewsWire | 2026-01-12 08:30:00 |
| IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer | ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States CAESAREA, Israel , Dec. 17, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, is expecting to report a significant increase in fourth quarter sales in North America compared to the same period last year. | PRNewsWire | 2025-12-17 08:30:00 |
| IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting | Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense® CAESAREA, Israel , Dec. 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that four abstracts featuring data from independent studies conducted by ProSense® users were accepted and presented at the Radiological Society of North America's ("RSNA") Annual Meeting, which took place from November 30 to December 4, 2025 in Chicago, Illinois. | PRNewsWire | 2025-12-10 08:30:00 |
| IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes | Cryogenic flow control enhances the efficacy and precision of cryoablation procedures Robust IP portfolio becomes increasingly strategic as global interest in IceCure's platform and next-generation cryoablation technologies grows following ProSense®'s recent FDA marketing authorization in low-risk breast cancer CAESAREA, Israel , Dec. 5, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled "Cryogen Flow Control" which relates to its next-generation XSense™ cryoablation system and probes. | PRNewsWire | 2025-12-05 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-02-23 | 2026-02-23 | View Filing |
| 6-K | 2026-02-09 | 2026-02-09 | View Filing |
| 6-K | 2026-01-12 | 2026-01-12 | View Filing |
| 6-K | 2026-01-09 | 2026-01-09 | View Filing |
| 6-K | 2026-01-08 | 2026-01-08 | View Filing |
| 6-K | 2025-12-17 | 2025-12-17 | View Filing |
| 6-K | 2025-12-10 | 2025-12-10 | View Filing |
| 6-K | 2025-12-05 | 2025-12-05 | View Filing |
| 6-K | 2025-12-03 | 2025-12-02 | View Filing |
| 6-K | 2025-11-19 | 2025-11-19 | View Filing |
| 6-K | 2025-11-18 | 2025-11-18 | View Filing |
| 6-K | 2025-11-14 | 2025-11-14 | View Filing |
| 6-K | 2025-11-10 | 2025-11-10 | View Filing |
| 6-K | 2025-11-03 | 2025-11-03 | View Filing |
| 6-K | 2025-10-17 | 2025-10-17 | View Filing |
| 6-K | 2025-10-03 | 2025-10-03 | View Filing |
| 6-K | 2025-09-30 | 2025-09-30 | View Filing |
| EFFECT | 2025-09-26 | 2025-09-26 | View Filing |
| 6-K | 2025-09-22 | 2025-09-22 | View Filing |
| POS AM | 2025-09-19 | 2025-09-19 | View Filing |
| 6-K | 2025-09-18 | 2025-09-18 | View Filing |
| 6-K | 2025-09-15 | 2025-09-15 | View Filing |
| F-3 | 2025-09-04 | 2025-09-04 | View Filing |
| 6-K | 2025-09-04 | 2025-09-04 | View Filing |
| 6-K | 2025-09-04 | 2025-09-04 | View Filing |
| 6-K | 2025-08-20 | 2025-08-20 | View Filing |
| 6-K | 2025-08-13 | 2025-08-13 | View Filing |
| EFFECT | 2025-08-05 | 2025-08-05 | View Filing |
| 6-K/A | 2025-08-01 | 2025-08-01 | View Filing |
| POS AM | 2025-08-01 | 2025-08-01 | View Filing |
| 6-K | 2025-08-01 | 2025-08-01 | View Filing |
| 424B3 | 2025-07-28 | 2025-07-28 | View Filing |
| 6-K | 2025-07-28 | 2025-07-28 | View Filing |
| 6-K | 2025-07-25 | 2025-07-25 | View Filing |
| 424B3 | 2025-07-16 | 2025-07-16 | View Filing |
| 6-K | 2025-07-16 | 2025-07-16 | View Filing |
| 6-K | 2025-07-10 | 2025-07-10 | View Filing |
| EFFECT | 2025-07-10 | 2025-07-10 | View Filing |
| 424B3 | 2025-07-09 | 2025-07-09 | View Filing |
| F-1/A | 2025-07-07 | 2025-07-07 | View Filing |
| F-1/A | 2025-07-03 | 2025-07-03 | View Filing |
| 6-K | 2025-07-03 | 2025-07-03 | View Filing |
| FWP | 2025-06-25 | 2025-06-25 | View Filing |
| 6-K | 2025-06-25 | 2025-06-25 | View Filing |
| F-1/A | 2025-06-25 | 2025-06-25 | View Filing |
| F-1 | 2025-06-16 | 2025-06-16 | View Filing |
| RW | 2025-06-16 | 2025-06-16 | View Filing |
| 6-K | 2025-06-09 | 2025-06-09 | View Filing |
| 6-K | 2025-05-28 | 2025-05-28 | View Filing |
| 6-K | 2025-05-21 | 2025-05-21 | View Filing |
| 6-K | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13D | 2025-05-14 | 2025-05-14 | View Filing |
| 6-K | 2025-04-30 | 2025-04-30 | View Filing |
| 6-K | 2025-04-10 | 2025-04-10 | View Filing |
| 20-F | 2025-03-27 | 2025-03-27 | View Filing |
| 20-F | 2025-03-27 | 2025-03-27 | View Filing |
| 6-K | 2025-03-27 | 2025-03-27 | View Filing |
| 6-K | 2025-03-20 | 2025-03-20 | View Filing |
| 6-K | 2025-03-18 | 2025-03-18 | View Filing |
| 6-K | 2025-03-17 | 2025-03-17 | View Filing |
| 6-K | 2025-03-10 | 2025-03-10 | View Filing |
| 6-K | 2025-02-24 | 2025-02-24 | View Filing |
| 6-K | 2025-02-04 | 2025-02-04 | View Filing |
| 6-K | 2025-01-27 | 2025-01-27 | View Filing |
| 424B5 | 2025-01-13 | 2025-01-13 | View Filing |
| 6-K | 2025-01-13 | 2025-01-13 | View Filing |
| 6-K | 2025-01-13 | 2025-01-13 | View Filing |
| 6-K | 2025-01-06 | 2025-01-06 | View Filing |
| 6-K | 2025-01-03 | 2025-01-03 | View Filing |
| 6-K | 2024-12-30 | 2024-12-30 | View Filing |
| 6-K | 2024-12-05 | 2024-12-05 | View Filing |
| 6-K | 2024-11-26 | 2024-11-26 | View Filing |
| 6-K | 2024-11-25 | 2024-11-25 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| F-1/A | 2024-11-08 | 2024-11-08 | View Filing |
| 6-K | 2024-11-08 | 2024-11-08 | View Filing |
| F-1/A | 2024-11-05 | 2024-11-05 | View Filing |
| 6-K | 2024-10-21 | 2024-10-21 | View Filing |
| F-1 | 2024-10-15 | 2024-10-15 | View Filing |
| 6-K | 2024-10-07 | 2024-10-07 | View Filing |
| 6-K | 2024-09-24 | 2024-09-24 | View Filing |
| 6-K | 2024-09-16 | 2024-09-16 | View Filing |
| 6-K | 2024-09-12 | 2024-09-12 | View Filing |
| 6-K | 2024-08-28 | 2024-08-28 | View Filing |
| 6-K | 2024-08-20 | 2024-08-20 | View Filing |
| S-8 | 2024-08-16 | 2024-08-16 | View Filing |
| 6-K | 2024-08-14 | 2024-08-14 | View Filing |
| 6-K | 2024-08-07 | 2024-08-07 | View Filing |
| 6-K | 2024-08-06 | 2024-08-06 | View Filing |
| 6-K | 2024-07-22 | 2024-07-22 | View Filing |
| 6-K | 2024-07-22 | 2024-07-19 | View Filing |
| 6-K | 2024-07-16 | 2024-07-16 | View Filing |
| 6-K | 2024-07-09 | 2024-07-09 | View Filing |
| 6-K | 2024-07-01 | 2024-07-01 | View Filing |
| 6-K | 2024-06-04 | 2024-06-04 | View Filing |
| 6-K | 2024-05-28 | 2024-05-28 | View Filing |
| 6-K | 2024-05-21 | 2024-05-21 | View Filing |
| 6-K | 2024-05-07 | 2024-05-07 | View Filing |
| 6-K | 2024-04-15 | 2024-04-15 | View Filing |
| 6-K | 2024-04-15 | 2024-04-15 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Gap | 13.74% | 0.99 | 39 | 0.45 | 0.19 | 14.68 |
| Keltner Channel Strategy | 6.88% | 1 | 19 | 0.56 | 0 | 7.81 |
| Bollinger Bands Strategy | 6.88% | 1 | 1 | 1.84 | 0 | 7.81 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | x |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |